Description
The Defense Logistics Agency (DLA) is soliciting offers for the supply of Febuxostat tablets (40 mg and 80 mg, 30‑tablet bottles) to meet DoD, VA, IHS, and BOP demand over a five‑year period. This is a commercial‑products requirements contract using the DIBBS electronic submission system, with an estimated quantity of 76,388 bottles of 40 mg and 36,627 bottles of 80 mg each base year, plus four optional years. Offerors must be registered in DIBBS, provide a subcontracting plan if a large business, and may be subject to a reverse‑auction process. The contract includes standard FAR/DFARS clauses, small‑business representations, and cybersecurity/telecommunications restrictions.
• Product: Febuxostat 40 mg & 80 mg tablets, 30‑count bottles (BTL).
• Estimated annual quantities: 76,388 bottles (40 mg) and 36,627 bottles (80 mg).
• Contract type: Requirements contract with up‑to‑five‑year base + options; price‑based evaluation.
• Submission window: Aug 25 2026 – Sep 24 2026 (electronic via DIBBS).
• Mandatory registrations: DIBBS, SAM; large businesses must submit a subcontracting plan.
• Potential reverse‑auction; award based on price and compliance.
• Key compliance: Small‑business size standards, prohibited telecom equipment, ethics code, reporting requirements.